Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Fintel reports that on March 4, 2025, Citigroup downgraded their outlook for Quest Diagnostics (NYSE:DGX) from Buy to Neutral ...

DGX outperforms the industry and the S&P 500 ... Key Insights Using the 2 Stage Free Cash Flow to Equity, Quest Diagnostics fair value estimate is US$339 Current share... Bio-Rad witnesses growth ...

No. 1: It is already the case that we’re selling DGX Cloud today, and there is a model for it to be transacted through the NPN. So that’s already in place. And No. 2: Of course, these are ...